SCHEMBL210295

SCHEMBL210295

O=C(O)c1ccc(OBOc2ccc(C(=O)O)cc2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 3/20 0.58
CA2 P00918 3/20 0.58
TSHR P16473 3/20 0.57
TP53 P04637 1/20 0.57
PARP15 Q460N3 1/20 0.52
PARP10 Q53GL7 1/20 0.52
KMT2A Q03164 1/20 0.52
SRD5A2 P31213 3/20 0.50
PKM P14618 1/20 0.50
HSD17B10 Q99714 1/20 0.48
CA12 O43570 1/20 0.48
CA3 P07451 1/20 0.48
TYR P14679 1/20 0.48
DRD1 P21728 1/20 0.48
CA4 P22748 1/20 0.48
CA6 P23280 1/20 0.48
CA5A P35218 1/20 0.48
CA7 P43166 1/20 0.48
CA9 Q16790 1/20 0.48
CA14 Q9ULX7 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28104658 0.87 CA1 (0.50) CA1CA2TSHRTP53PARP15
SCHEMBL2628977 0.84 CA1 (0.56) CA1CA2TSHRTP53PARP15
SCHEMBL540837 0.79 PARP10 (0.64) CA1CA2PARP15PARP10KMT2A
SCHEMBL655335 0.79 MAPT (0.64) TSHRKMT2AALDH1A1SMN1; SMN2LMNA
SCHEMBL6746609 0.77 TSHR (0.67) CA1CA2TSHRTP53PARP15
SCHEMBL5581520 0.77 PARP10 (0.78) CA1CA2TSHRTP53PARP15
SCHEMBL766069 0.77 PARP10 (0.78) CA1CA2TSHRTP53PARP15
Terephthalic Acid SCHEMBL9861713 0.77 PARP10 (0.78) CA1CA2TSHRTP53PARP15
SCHEMBL22281 0.77 PARP10 (0.78) CA1CA2TSHRTP53PARP15
Terephthalic Acid SCHEMBL1655 0.76 TSHR (1.00) CA1CA2TSHRTP53SRD5A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 619 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240123074-A1 MINIMALLY TOXIC PRODRUGS COBIORES NV (BE) 2024-04-18 US claimed
US-11262349-B2 Multiplexed immune cell assays on a micropillar/microwell chip platform CLEVELAND STATE UNIVERSITY (US) 2022-03-01 US claimed
CN-110055063-A A kind of B, N, fluorescent orange carbon dots of S codope and its preparation method and application 山西大学 2019-07-26 CN claimed
CN-110023475-A The stabilisation of enzyme in the composition 巴斯夫欧洲公司 2019-07-16 CN claimed
US-20190107532-A1 MULTIPLEXED IMMUNE CELL ASSAYS ON A MICROPILLAR/MICROWELL CHIP PLATFORM CLEVELAND STATE UNIVERSITY (US) 2019-04-11 US claimed
CN-107858097-A Super-hydrophobic fluorosilicone resin ceramic antifouling agent and preparation method thereof 湖南辰砾新材料有限公司 2018-03-30 CN claimed
EP-3149138-A1 WATER CLUSTER-DOMINANT BORONIC ACID ALKALI SURFACTANT COMPOSITIONS AND THEIR USE The Procter & Gamble Company (US) 2017-04-05 EP claimed
CN-103748142-B Reversibly crosslinked micelle systems THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2016-04-27 CN claimed
WO-2015184209-A1 WATER CLUSTER-DOMINANT BORONIC ACID ALKALI SURFACTANT COMPOSITIONS AND THEIR USE THE PROCTER & GAMBLE COMPANY (US) 2015-12-03 WO claimed
US-20150344817-A1 WATER CLUSTER-DOMINANT BORONIC ACID ALKALI SURFACTANT COMPOSITIONS AND THEIR USE THE PROCTER & GAMBLE COMPANY 2015-12-03 US claimed
EP-1294405-A2 PRODRUG COMPOUNDS CLEAVABLE BY THIMET OLIGOPEPTIDASE CORIXA CORPORATION (US) 2003-03-26 EP claimed
EP-1294404-A2 PRODRUG COMPOUNDS WITH AN OLIGOPEPTIDE HAVING AN ISOLEUCINE RESIDUE CORIXA CORPORATION (US) 2003-03-26 EP claimed
EP-1294403-A2 TRIPEPTIDE PRODRUG COMPOUNDS CORIXA CORPORATION (US) 2003-03-26 EP claimed
WO-2002100353-A2 CD10-ACTIVATED PRODRUG COMPOUNDS MEDAREX, INC. (US) 2002-12-19 WO claimed
US-20020142955-A1 Enzyme-cleavable prodrug compounds E. R. SQUIBB & SONS, L.L.C. 2002-10-03 US claimed
US-6451881-B1 Oligomeric dispersant MBT HOLDINGAG (CH) 2002-09-17 US claimed
WO-2002000263-A2 TRIPEPTIDE PRODRUG COMPOUNDS MEDAREX, INC. (US) 2002-01-03 WO claimed
WO-2001095943-A2 PRODRUG COMPOUNDS WITH AN OLIGOPEPTIDE HAVING AN ISOLEUCINE RESIDUE MEDAREX, INC. (US) 2001-12-20 WO claimed
WO-2001095945-A2 PRODRUG COMPOUNDS CLEAVABLE BY THIMET OLIGOPEPTIDASE MEDAREX, INC. (US) 2001-12-20 WO claimed
US-6133347-A CEMENT AND A DISPERSANT COMPRISING THE REACTION PRODUCT OF A WATER SOLUBLE NONIONIC POLYMER NONADSORBING TO CEMENT PARTICLES, SUCH AS POLYOXYALKYLENE GLYCOLS, AND SPECIFIED FUNCTIONAL MOIETY THAT ADSORB ONTO A PARTICLE MBT HOLDING AG (CH) 2000-10-17 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240123074-A1 MINIMALLY TOXIC PRODRUGS ALG8, ALG1, LNPEP CA1 901/4885CA2 1548/4885TSHR 4425/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.